Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. (HNGE) reported that President James Pursley had 6,326 shares of Class A Common Stock withheld on September 1, 2026 to satisfy federal and state tax withholding obligations arising from the vesting of restricted stock units, in an exempt transaction under Section 16b-3(e).
The shares were relinquished and cancelled in exchange for the issuer paying these taxes, leaving Pursley with 699,909 shares held directly after the transaction; no Rule 10b5-1 trading plan is reported.
Hinge Health, Inc. (HNGE) reported that Chief Financial Officer James Budge had 9,986 shares of Class A Common Stock withheld on September 1, 2026 to cover exercise price or tax liabilities related to vesting restricted stock units. The shares were relinquished and cancelled in exchange for the company paying his federal and state tax withholding obligations, leaving him with 404,623 shares held directly. No Rule 10b5-1 trading plan is reported.
Hinge Health, Inc. (HNGE) received a Rule 144 notice from JL 2025 Family Trust LLC, a 10% stockholder, covering planned sales of Class A common stock. The filing lists 8,382 Class A shares with an aggregate market value of $754,380.00, with 62,468,721 Class A shares outstanding as of 09/01/2026. It also discloses an in-kind distribution of 33,528 Class A shares dated 08/10/2026 from various Insight entities. The notice further details extensive Class A share sales in June–August 2026 by multiple Insight Venture Partners funds and an individual associated with those entities.
Hinge Health, Inc. (HNGE) has a notice under Rule 144 covering potential sales of Class A common stock for the account of the Jeffrey Lieberman 2012 Family Trust, identified as a 10% stockholder. Raymond James & Associates, Inc. is listed as the broker.
The notice also lists extensive recent sales of Hinge Health Class A shares by various Insight Venture Partners funds, with multiple large transactions in June–August 2026, including individual blocks of several hundred thousand shares at multi-million-dollar aggregate values.
Hinge Health, Inc. (HNGE) received a notice under Rule 144 for the proposed sale and distribution of Class A common stock for the account of 10% stockholder Jeffrey Lieberman. Raymond James & Associates, Inc. is listed as broker for certain sales, and various Insight Venture Partners entities are identified for an in-kind distribution of 46,002 shares on August 10, 2026. The notice also details multiple prior open‑market sales of HNGE Class A shares by Insight funds in June–August 2026.
Hinge Health, Inc. (HNGE) has a notice of proposed sale on behalf of 10% stockholder Thomas Michael Triplett under Rule 144. The filing covers the potential disposition of 66,967 common shares through Raymond James & Associates, Inc., with an indicated aggregate market value of $6,027,030.00. Hinge Health common shares outstanding are listed as 62,468,721. The contemplated transaction is described as an in-kind distribution from various Insight entities, and the notice also lists multiple recent Class A share sales by Insight Venture Partners-affiliated funds over June–August 2026, including several multi-million-dollar transactions.
Hinge Health, Inc. (HNGE) reported that entities affiliated with Bessemer Venture Partners sold shares of its Class A Common Stock. On August 25, 2026, Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. sold shares at a weighted average price of $91.08, and on August 26, 2026 they sold additional shares at a weighted average price of $91.71. Reporting person Robinson Elliott is a partner at Bessemer Venture Partners and has only an indirect, passive economic interest in these securities and disclaims beneficial ownership except to the extent of any pecuniary interest.
Hinge Health, Inc. (HNGE) received a Rule 144 notice indicating that Bessemer Venture Partners X Institutional intends to sell up to 121,050 Class A shares through Merrill Lynch on the NYSE, with an aggregate market value of $10,892,079. The notice states that 62,468,721 Class A shares were outstanding. The shares being sold were acquired in a private placement on 02/04/2020 for cash. The notice is dated 08/25/2026.
Hinge Health, Inc. (HNGE) shareholder Bessemer Venture Partners X filed a Form 144 notice to sell up to 128,950 Class A shares through Merrill Lynch. The shares have an aggregate market value of 11,602,921, with 62,468,721 Class A shares outstanding. The proposed sale date is 08/25/2026. The shares were acquired in a Private Placement on 02/04/2020 for cash.
Hinge Health, Inc. (HNGE) reported that its Chief Financial Officer, James Budge, made a bona fide gift of 11,563 shares of Class A Common Stock on 2026-08-24. After this gift, he directly holds 414,609 shares of Class A Common Stock.